Business
DOCM: Strong Rx and TeleClinic growth, fully underwritten CHF 200m raise, EBITDA break-even in 2026
DOCM: Strong Rx and TeleClinic growth, fully underwritten CHF 200m raise, EBITDA break-even in 2026
About this update from Docmorris Ltd
Q1 2025 saw 13% revenue growth, with Rx up 52% and TeleClinic revenue more than doubling. A CHF 200 million capital raise is fully underwritten to fund growth, with EBITDA break-even targeted in 2026 and positive free cash flow in 2027. Based on This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.